Breaking News, Collaborations & Alliances

Aurigene & Vipergen Partner to Co-Market & Offer DEL Screening Technologies to Customers

Will also co-develop new DELs with an emphasis on novel chemical diversity and drug-likeness to further strengthen their service offering.

Aurigene Pharmaceutical Services Ltd., a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DNA encoded library (DEL) technologies, have partnered to co-market and offer DEL screening technologies to global customers as a standalone service or as an integrated drug discovery service.
 
The two companies will also co-develop new DELs with an emphasis on novel chemical diversity and drug-likeness to further strengthen their service offering.
 
Vipergen’s high-fidelity DEL screening technologies are a strategic addition to Aurigene’s existing small molecule discovery capabilities, from compound resynthesis to candidate nomination. With the addition of hit screening capabilities, Aurigene will be able to enhance its Integrated Drug Discovery (IDD) service offering to its global customers.
 
“The partnership with Vipergen emphasizes our commitment to accelerating innovation and customer-centric approach. The recent launch of Aurigene.AI for small molecules and DEL partnership with Vipergen aim to reduce the hit finding timelines. Vipergen’s proven track record, with more than 90 partnerships with big pharma and biotech companies, and their streamlined hit finding platform, makes Vipergen the ideal strategic partner for us,” said Akhil Ravi, CEO, Aurigene.
 
“We are excited to partner with Aurigene, a global CRDMO focused on customer service. Aurigene’s drug discovery capabilities and global reach makes it a perfect match for Vipergen. I am looking forward to a successful partnership, and to offering our proprietary technologies to global customers,” said Nils Jakob Vest Hansen, PhD, CEO, Vipergen.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters